Takeda (NYSE:TAK) announced that Japan’s Ministry of Health, Labour and Welfare approved ORZEYFUL (oveporexton) for adults with narcolepsy type 1, making it the company’s third global approval for the treatment.
Acadia Pharmaceuticals (NASDAQ:ACAD) announced that the European Commission approved DAYBU (trofinetide) for Rett syndrome in adults and pediatric patients aged five years and older, making it the first approved Rett syndrome treatment in the European Union.
Biogen (NASDAQ:BIIB) and Eisai announced that LEQEMBI IQLIK, a once-weekly subcutaneous lecanemab-irmb autoinjector, is now available in the United States for adults with early Alzheimer’s disease.
Scholar Rock (NASDAQ:SRRK) removed Catalent Indiana as a commercial fill-finish facility from its apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA), with FDA review continuing using an alternate facility.
Alvotech (NASDAQ:ALVO) entered a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering two biosimilar candidates, AVT34 and AVT87, with potential value of approximately $150 million.
Milestone Pharmaceuticals (NASDAQ:MIST) enrolled the first patient in ReVeRA-301, a pivotal Phase 3 trial evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate (AFib-RVR).
Werewolf Therapeutics (NASDAQ:HOWL) and Ambros Therapeutics entered an all-stock merger agreement that will create a Nasdaq-listed biotechnology company focused on developing neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1).
AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy.
Cosmos Health (NASDAQ:COSM) signed an exclusive distribution agreement with Innova Healthcare for its Sky Premium Life food supplements in Saudi Arabia, including an initial purchase order of 126,000 units.
Sol-Gel (NASDAQ:SLGL) reported second quarter 2026 revenue of $0.6 million, down from $17.3 million a year earlier due mainly to a prior-year $16.7 million intellectual property sale to Mayne.
Telix Pharmaceuticals (NASDAQ:TLX) reported H1 2026 group revenue of US$477 million, up 22% year-over-year, while profit after tax increased to US$38 million from a US$2 million loss in the same period last year.
Jaguar Health (NASDAQ:JAGX) reported second-quarter 2026 net revenue of $1.2 million, down 59% year over year, following the U.S. commercialization transfer of Mytesi and Canalevia-CA1 to Future Pak affiliate Woodward Specialty.
